Pregled bibliografske jedinice broj: 1139186
Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center
Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center // Archives of Gynecology and Obstetrics, 301 (2020), 5; 1227-1233 doi:10.1007/s00404-020-05522-5 (međunarodna recenzija, članak, stručni)
CROSBI ID: 1139186 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Fertility-sparing surgery for patients with
malignant ovarian germ cell
tumors: 10 years of clinical experience from a
tertiary referral center
Autori
Mikuš, Mislav ; Benco, Nikolina ; Matak, Luka ; Planinić, Pavao ; Ćorić, Mario ; Lovrić, Helena ; Radošević, Velena ; Puževski, Tomislav ; Bajt, Mirna ; Vujić, Goran
Izvornik
Archives of Gynecology and Obstetrics (0932-0067) 301
(2020), 5;
1227-1233
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
Adjuvant chemotherapy ; Fertility-sparing surgery ; Malignant ovarian germ cell tumors ; Reproductive outcome.
Sažetak
Purpose: To describe a case series of patients with malignant ovarian germ cell tumors (MOGCT) treated exclusively with fertility-sparing surgery (FSS) with or without adjuvant chemotherapy. Methods: We retrospectively reviewed the records of 27 patients with MOGCT treated in the Department of Obstetrics and Gynecology, University Hospital Center Zagreb, Croatia, between January 2009 and July 2019. Results: The median age at diagnosis was 22 years, and the main symptom was abdominal distension (57.0%). The most prevalent histological subtype was immature teratoma (n = 13, 48.1%). Twenty- three patients (85.2%) had laparotomy and 4 (14.8%) had laparoscopy, without conversions. Lymphadenectomy was performed in 16 (59.3%) patients, with 184 removed lymph nodes, and omentectomy was performed in 19 (70.4%) patients. The rate of chemotherapy administration was 81.5%. The follow-up length ranged between 6.30 and 115.1 months (median: 49.60 months). No patient experienced tumor recurrence. The rate of complete gross resection was 100%. At the time of analysis, all patients were alive and disease free. Fifty percent of patients who actively tried to conceive after FSS became pregnant, with 12 deliveries. Conclusion: This study suggests that FSS is a safe treatment option for MOGCT, regardless of tumor stage and histological type.
Izvorni jezik
Engleski
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb,
Klinika za dječje bolesti,
Opća bolnica Zadar
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE